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Abstract
Inflammatory bowel disease (IBD) affects patients during 
their peak reproductive years. This raises important ques-
tions, in both patients and healthcare providers, regarding 
conception, pregnancy, and breastfeeding. Lack of informa-
tion and insufficient communication among healthcare pro-
viders can leave patients with limited information and even 
contradictory advice. Given the fact that pregnant and/or 
breastfeeding IBD patients are excluded from clinical studies 
the evidence on many questions related to pregnancy and 
postpartum period is limited. However, there exists increas-
ing data from case series and cohort studies that allows to 
provide clinical guidance. The overarching concept is that 
optimizing the mother’s health is critical for optimizing the 
health of the unborn child and benefit of continuing medical 
therapy in IBD during pregnancy outweighs possible risks in 
most instances. This paper provides an up-to-date system-
atic review of the literature on IBD in pregnancy and pro-
poses guidance to questions frequently encountered by 
healthcare professionals. © 2020 S. Karger AG, Basel
Introduction
Inflammatory bowel disease (IBD) is represented by 
Crohn’s disease (CD) and ulcerative colitis (UC). The 
peak age onset of these diseases coincides with childbear-
ing years and approximately 25% of patients will have 
their first child after being diagnosed with IBD [1]. These 
diseases may therefore have an impact on fertility, preg-
nancy, and lactation.
Managing IBD during pregnancy can be challenging 
for healthcare providers since the health of both the 
mother and the fetus must be considered to take the op-





crucial, especially at the time of conception, as uncon-
trolled disease is associated with higher risks of adverse 
pregnancy outcomes for both, the mother [2, 3] and the 
fetus [4–8]. 
Many concerns among IBD patients exist regarding 
the impact of the disease during pregnancy and the con-
sequences on the child. A report suggested that 50% of 
women with IBD were worried about infertility, one-
fourth believed that it was more important to tolerate 
symptoms than to expose the fetus to their treatment, 
one-third believed that any medications given for IBD 
would be dangerous for their child, and three-fourths 
were concerned about transmitting the disease to their 
offspring [9–11]. These concerns can explain why certain 
women stop their treatment before conception or during 
pregnancy and lactation, despite the increasing evidence 
from recent studies confirming the benefit of continuing 
medical therapy in IBD during pregnancy [12–19]. 
Counseling patients during this emotional and impor-
tant period of their lives is important. The management 
should be multidisciplinary including gastroenterologist 
and IBD nurse, obstetrician, primary care provider, pe-
diatrician and if necessary surgeon. Communication be-
tween these care providers is crucial to avoid ambivalent 
or even contradictory counseling, which represents an 
extra source of anxiety for patients as well as potentially 
suboptimal adherence. 
In 2015, The European Crohn’s and Colitis Organisa-
tion published the second consensus on reproduction 
and pregnancy in IBD, which includes mainly data pub-
lished until 2013 [20]. Important concepts have emerged 
recently from case-control and large cohort studies. This 
article seeks to incorporate up-to-date evidence relating 
to the management of IBD before conception, during 
pregnancy, and the postpartum period. 
Impact of IBD on Fertility 
Patients with IBD have fewer children compared to the 
general population, which is partly explained by the 
choice of some patients not to have children. Voluntary 
childlessness is reported in 17% of women with IBD com-
pared to 6% of women in the general population [21]. 
This choice results largely from fears that are often unjus-
tified [22], reinforcing the importance of accurate coun-
seling in this population to help them make their deci-
sion. A systematic review of 11 studies found no increased 
rate of infertility issues in women and men with IBD in 
remission and without a history of surgery [23]. However, 
the impact of IBD activity and certain treatments is im-
portant for both men and women regarding fertility and 
pregnancy outcomes. 
Women
Medical therapy for IBD, including all biologic thera-
pies, steroids, thiopurines, methotrexate, and mesala-
mine, does not decrease fertility [24–27]. However, wom-
en with active IBD may have decreased fertility [28–30] 
related to dyspareunia in patients with severe perianal or 
pelvic disease, fallopian tube occlusion secondary to pel-
vic adhesions, and ovarian dysfunction related to chronic 
illness or nutritional deficiencies [11]. Evidence suggests 
that patients having undergone proctocolectomy with il-
eal-pouch anal anastomosis (IPAA), proctectomy, and 
permanent ostomies are at increased risk for infertility. 
The decrease of fertility is mainly due to inflammation 
and scarring of the fallopian tubes [31–33]. Choosing a 
laparoscopic technique compared to laparotomy proba-
bly decreases infertility risk, and there is therefore no rea-
son to avoid important surgery because a patient wants to 
be pregnant [34, 35]. Inability to conceive for 6 months 
should lead to referral for infertility evaluation, especially 
if there is a history of open pelvic surgery [36]. IBD wom-
en who have undergone IPAA have a success rate for in 
vitro fertilization comparable to those without IBD or 
with IBD but without surgery [37]. 
Men
Less is known about the impact of disease activity and 
IBD specific medications on men’s fertility and pregnan-
cy outcome. A large internet-based voluntary cohort of 
IBD patients suggested that ensuring optimal control of 
disease is also important in male patients attempting to 
have children [38]. Men reported difficulties in conceiv-
ing more often when they had active or recently active 
disease. This association is probably explained by several 
factors such as decrease of desire for sexual activity re-
lated to anxiety and depression, effect of inflammation, 
and/or adverse effects of medications on semen charac-
teristics. Several drugs may interfere with motility or 
sperm count. Sulfasalazine causes dose-related decrease 
in both sperm count and motility that is reversible. It 
should therefore be replaced by other 5-ASA formula-
tions in men wishing to procreate [39]. Corticosteroids 
can cause a reversible decrease in sperm motility and con-
centration, but this observation does not seem to affect 
fertility in men [25, 40]. Methotrexate (MTX) is contra-
indicated due to its teratogenicity and risk of oligosper-
mia, which is reversible 4–5 months after stopping the 
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drug [41, 42]. No evidence of effect on fertility outcomes 
is described for either thiopurine or antitumor necrosis 
factor (TNF) used by the father at the time of conception, 
although it has not been extensively examined [43–46]. 
Male patients suffering from UC who undergo IPAA may 
experience erectile dysfunction and retrograde ejacula-
tion, also having surgery done at specialized center with 
laparoscopic approach help lowering the risks [47, 48].
Effect of Pregnancy on the Course of IBD 
Risk of relapse during pregnancy in IBD women with 
stable disease is approximately 30%, which is similar to 
nonpregnant patients [7, 49, 50]. Conversely, two-thirds of 
patients with active disease at conception will have persis-
tent active disease during pregnancy [2, 51]. Pregnancy also 
seems to lower the risk of long-term disease relapse [52, 53]. 
Effect of IBD on pregnancy, Fetal, and Neonatal 
Outcomes
Data on incidence of fetal abnormalities are conflict-
ing, but reported risks are low [10, 51, 54]. Current evi-
dence suggests that most of the time women who have 
quiescent disease before pregnancy have pregnancy out-
comes similar to women without IBD. A 2-fold increased 
risk of low gestational weight compared with non-IBD 
patients has been reported in cohort studies [55]. Active 
disease is associated with higher rates of adverse out-
comes such as fetal loss and stillbirth, preterm delivery, 
low birth weight, small for gestational age, thromboem-
bolic events, cesarean section, increased neonatal inten-
sive care admission, and low APGAR score [56, 57]. Ad-
verse events result also on the degree of activity and its 
timing during pregnancy. It is difficult to determine 
whether disease activity itself or other confounding fac-
tors as discontinuation of treatments influence the in-
creased risks. As such, it is recommended to control the 
disease prior to conception and to keep the mother in 
remission and well-nourished during pregnancy.
Monitoring of Disease Activity during Pregnancy
The diagnosis of active disease in pregnant IBD pa-
tients can be tricky as biological parameters such as C-
reactive protein (CRP), hemoglobin concentration, 
erythrocyte sedimentation rate, and serum albumin are 
affected by pregnancy [51]. To take appropriate decisions 
and obtain and maintain remission, its crucial to care-
fully monitor patients during the prenatal period.
Endoscopy
Recent data suggest that endoscopy is relatively safe 
during pregnancy. It is contraindicated only in obstetric 
complications such as placental abruption, ruptured 
membranes, or eclampsia. If endoscopy is necessary, the 
indication should be strong, and the procedure per-
formed by experienced endoscopists to decrease the time 
of the procedure. Whenever possible, the procedure 
should be postponed after the first trimester because of 
the organogenesis. Pregnant women should be positioned 
in left lateral position or left pelvic tilt to avoid aortic and 
vena cava compression. An unsedated flexible sigmoid-
oscopy can be done in any trimester of pregnancy. Colo-
noscopy should be done with obstetric anesthesia moni-
toring. Benzodiazepines should be avoided, but propofol 
is considered safe during pregnancy, also it should prefer-
ably not be administered during the first trimester due to 
insufficient data. Fetal heartbeat should be detected be-
fore and after endoscopy and obstetric support should 
always be available.
Imaging
The safest methods of imaging during pregnancy remain 
ultrasound and magnetic resonance imaging. However, the 
view of abdominal contents with ultrasound can be limited 
especially in advanced gestation. When ultrasound results 
are inconclusive or for more complex cases magnetic reso-
nance imaging without contrast can be proposed. In the 
absence of safety data, gadolinium is contraindicated dur-
ing pregnancy. Abdominal X-ray and computed tomogra-
phy should be avoided where possible because of concerns 
about side effects of irradiation on the fetus. 
Biomarkers of IBD Activity during Pregnancy and 
Therapeutic Drug Monitoring
CRP and fecal calprotectin (FC) are helpful noninva-
sive markers used in IBD patients with relatively good cor-
relation with disease activity. Also their accuracy and cor-
relation with activity during pregnancy have not been well 
established [58–61], increasing body of evidence suggests, 
that FC may serve a reliable biomarker in all gestational 
periods and is less likely being prone to alterations as CRP. 
A prospective evaluation of 30 pregnant women taking 
thiopurines found that maternal thiopurine metabolism 
changed during pregnancy, with 6-thioguanine concen-





tration increasing as pregnancy progressed [62]. No ma-
ternal biochemical toxicities resulted from this shift, and 
thiopurine metabolism reverted to baseline after delivery. 
Few data are available on maternal serum levels in preg-
nancy. A small sample size study by Seow et al. [63] ob-
served that infliximab (IFX) levels increased during preg-
nancy while adalimumab (ADA) levels remained stable. 
A recent prospective single-center cohort study suggested 
that ADA may be continued longer during pregnancy be-
cause transportation over the placenta is lower than for 
IFX [64]. Interestingly, a recent work including 12 pa-
tients on IFX and 4 patients on ADA with at least 2 intra-
partum measurements suggested that maternal drug lev-
els remain stable in patients on stable dosing of IFX or 
ADA in remission during pregnancy [65]. Further data 
are required to determine if and how pregnancy influ-
ences the pharmacokinetics of biologic treatments. Ex-
perts recommend in clinical practice to check maternal 
trough levels during the second trimester and adapt dos-
ing appropriately during the third trimester in order to 
give the maximum interval possible before delivery [27].
Drug Safety in Pregnancy
Many women with IBD will stop their medication be-
fore or during pregnancy because of their concerns about 
drug safety, which may lead to increased risk of relapse 
and undesirable pregnancy outcome [66, 67].
Pregnant and breastfeeding women are typically ex-
cluded from clinical trials, and randomized controlled 
trials on safety data on medications are lacking. However, 
with multiple registry, cohort, and database sources, the 
safety of IBD medications (except for methotrexate) has 
been supported in the recent literature for conception, 
pregnancy, and lactation, even if the overall evidence is 
still poor and the strength for most of the recommenda-
tions still weak.
Recently, the US Food and Drug Administration has 
abandoned the product letter categories (A, B, C, D, and 
X) and replaced them by detailed subsections (human, 
animal, and pharmacological) describing available infor-
mation on potential risks and benefits for the mother, the 
fetus, and breastfed children [27] (Table 1). 
Antibiotics
Metronidazole and ciprofloxacin are commonly pre-
scribed in IBD patients. A meta-analysis of first-trimester 
quinolone exposure did not detect any particular in-
creased risk [68]. Conversely, the use of metronidazole is 
controversial in pregnancy because 1 case-control study 
suggested a possible increased risk for oral clefts when 
used in the first trimester. However, 2 meta-analyses and 
1 systematic review found no increased risk for congeni-
tal anomalies [69]. Amoxicillin-clavulanic acid is consid-
ered to be safe during pregnancy [70]. Rifaximin should 
be avoided in human pregnancy as no safety data have 
been published in human pregnancy and animal studies 
revealed evidence of teratogenicity. Several large trials are 
ongoing regarding the use of probiotics in pregnancies, 
and preliminary results reported improvement in certain 
outcomes including preterm birth, allergies, and infec-
tions in children [71]. 
Aminosalicylates
Aminosalicylates are commonly used to treat flares of 
mild to moderate UC and for maintenance of remission. 
Aminosalicylates, including sulfasalazine, are considered 
safe in pregnancy up to 3 g/day and should be continued 
in patients in whom remission has been obtained prior to 
conception [72, 73].
Sulfasalazine interferes with folate synthesis by inhibit-
ing dihydrofolate reductase and pregnant women taking 
sulfasalazine should receive high-dose folic acid supple-
mentation (2 mg/day) to prevent neural tube defects [74]. 
Mesalamine derivatives can be continued during preg-
nancy with the exception of Asacol that contains in its 
coating dibutyl phthalate, which has been associated with 
congenital anomalies in animals at doses > 190 times the 
therapeutic human dose [75]. Mesalamine enemas and 
suppositories may be continued without any risk.
Corticosteroids
Corticosteroids may be necessary during pregnancy to 
treat disease flares. 
Older studies suggested that exposure to steroids dur-
ing the first trimester may be associated to an increased 
risk of cleft lip and palate development [76]. This obser-
vation was not reported in a large Danish cohort of pa-
tients, who were exposed to any form of corticosteroids 
during the first trimester (OR 1.05; 95% CI 0.80–1.38) 
[77]. In the Pregnancy in IBD and Neonatal Outcomes 
(PIANO) registry, the use of steroids was associated with 
an increased risk of certain maternofetal adverse events, 
such as preterm birth (OR 1.8; 95% CI 1.0–3.1), low birth 
weight (OR 2.8; 95% CI 1.3–6.1), and gestational diabetes 
(OR 2.8; 95% CI 1.3–6.0) [78]. Therefore, patients on cor-
ticosteroids during pregnancy should receive blood pres-
sure surveillance, glucose tolerance testing, and serial 
growth scans in the third trimester. Literature on the safe-
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Table 1. IBD treatment during pregnancy (adapted from [27] and [114])
Drug Pregnancy safety Comments
Antibiotics
Amoxicillin with clavulanic acid Low risk. Limited data Preferred antibiotic during pregnancy
Ciprofloxacin Low risk. Animal data reported anomalies Short courses for perianal disease
Metronidazole Low risk. Avoid first trimester. Possible risk 
of cleft lip
Short courses for perianal disease
Rifaximin Teratogenicity described in animal models Avoid
Aminosalicylates
Balsalazide Low risk Maintain prepregnancy dose
Mesalamine Low risk. Exception: asacol contains dibutylphtalate 
coating reported to be teratogenic in animal models
Maintain prepregnancy dose. Switch Asacol to another mesalamine agent with equivalent 
dose
Sulfasalazine Low risk Maintain prepregnancy dose. Increase folic acid to 2 mg daily
Corticosteroids
Budesonide Low risk Short courses
Prednisone Moderate risk. Mother: possible increase 
risk of gestational diabetes, adrenal insufficiency, 
premature rupture of membranes. Child: possible 
increase risk of orofacial cleft (first-trimester 
exposure), preterm birth, infections
Short courses. Use steroid-sparing agents when possible
Immunomodulators
Cyclosporine Possible but limited data with reported increased 
risk of pregnancy complications, preterm 
birth, low birth weight
Maintain prepregnancy dose
Methotrexate Contraindicated: teratogenic and abortifacient Women must stop the drug 3–6 months before attempting conception
Thiopurines (azathioprine, 
6-mercaptopurine)
Low risk in monotherapy Increased risk of infant 
infections in combination therapy
Maintain prepregnancy dose in monotherapy
If patient on combotherapy is in clinical and endoscopic remission with adequate trough 
levels, consider stopping thiopurine and continuing biologic monotherapy
No introduction during pregnancy  due to long delay of action and unpredictable risk of 
developing medullary suppression or pancreatitis
Small molecules
Tofacitinib Human data very limited
Biologics
Anti-TNF-α
IFX Low risk in monotherapy Maintain prepregnancy dosing. Consider 
decreasing the dose or increasing interval 
of administration depending on second 
trimester trough levels. Continue dosing 
until 8–10 week before delivery
Maintain prepregnancy dosing. Stop around 
week 20–22 in patient in remission
ADA Low risk in monotherapy Maintain prepregnancy dosing. Continue 
dosing until 3–4 week before delivery
Maintain prepregnancy dosing. Stop around 
week 20–22 in patient in remission
GM Low risk in monotherapy Maintain prepregnancy dosing. Continue 
dosing until 4–6 week before delivery
Maintain prepregnancy dosing. Stop around 
week 20-22 in patient in remission
CZP Very low risk. Does not actively cross placenta Maintain prepregnancy dosing. Continue 
scheduled dosing through pregnancy
Maintain prepregnancy dosing. Continue 
scheduled dosing through pregnancy
Anti-integrin
VDZ Low risk in monotherapy. Limited data Maintain prepregnancy dosing. Continue 
dosing until 8–10 week before delivery
Maintain prepregnancy dosing. Stop around 
week 20–22 in patient in remission
Anti-interleukins
UST Low risk in monotherapy. Limited data Maintain prepregnancy dosing. Continue 
dosing until 8–10 week before delivery
Maintain prepregnancy dosing. Stop around 
week 20–22 in patient in remission





ty of using budesonide during pregnancy is more limited, 
but this drug appears to be a safe option for treatment of 
CD [79]. To our knowledge, there are no data available 
on the use of budesonide MMX or beclomethasone di-
proprionate during pregnancy.
In conclusion, the use of steroids is possible during 
pregnancy, and the benefit of disease control outweighs 
the risk of exposure. It is difficult to separate the effect of 
disease activity from a side effect of the drug as cortico-
steroids use reflects that disease is not in remission. Pro-
longed exposure should be avoided, and this drug should 
not be considered as a maintenance strategy treatment. 
Methylprednisolone and hydrocortisone should be the 
molecules of choice as their increased placental metabo-
lism reduces the risk of fetal exposure compared to dexa-
methasone or betamethasone.
Immunomodulators
MTX is an antimetabolite that blocks the synthesis of 
thymidine. Exposure to MTX during organogenesis can 
lead to multiple malformations, mainly of limbs and skull 
known as methotrexate embryopathy. This drug is there-
fore contraindicated during conception and pregnancy. 
A woman of childbearing age on MTX should receive ef-
fective contraception. If accidentally conception occurs, 
therapeutic abortion should be discussed, but not neces-
sarily performed [20]. In addition, after discontinuation 
of treatment, women should wait 3–6 months before at-
tempting to become pregnant because of the long half-life 
of terminal elimination of the drug [80, 81].
Thiopurines (azathioprine and 6-mercaptopurine) in-
terfere with the synthesis of nucleic acid causing chromo-
some damage. These drugs have been reported to be terato-
genic in animal studies at doses similar to those used in hu-
mans, but administration in these studies was 
intraperitoneal or parenteral, which significantly increased 
the bioavailability of the drug [82–86]. However, recent 
studies agreed on the safety of thiopurines both on the con-
genital malformation risk and fetal complications [87]. The 
strongest data supporting safety come from a multicenter 
retrospective study comparing disease activity and preg-
nancy outcomes of 187 patients treated with thiopurines, 66 
patients treated with anti-TNF agents, and 318 unexposed 
IBD patients. In this study, no difference was found in preg-
nancy complications among the groups and multivariate 
analysis reported favorable global pregnancy outcomes, de-
fined as a decreased rate of spontaneous abortion and lack 
of obstetric complications, associated with thiopurines in-
take [86]. In the PIANO registry, no increased risk of con-
genital anomalies or pregnancy complications was ob-
served among > 335 thiopurine-exposed pregnancies [88]. 
Literature is conflicting on the risk of infection in children 
aged 9–12 months exposed to thiopurine plus anti-TNF 
combination therapy. Some authors reported an increased 
risk of infection (relative risk 1.50; 95% CI 1.08–2.09) [88], 
while others did not [89]. In conclusion, it is reasonable to 
continue thiopurine monotherapy during pregnancy to 
maintain remission, as the risks of active disease likely out-
weigh the risks associated with thiopurine use. Starting 
these treatments during pregnancy should be avoided be-
cause of the long delay of action and the unpredictable risk 
of developing medullary suppression or pancreatitis.
Calcineurin inhibitors act by suppressing the produc-
tion of interleukins 2 and 3, inhibiting chemotaxis of neu-
trophils and inducing apoptosis in T cells. Data on calci-
neurin inhibitor in pregnancy are mainly extrapolated 
from transplant literature. A systematic review in IBD re-
ported a possible link between their use and the occur-
rence of materno-fetal complications as hypertension, 
preeclampsia, gestational diabetes, preterm birth, low 
birth weight, and small-for-gestational-age neonates 
[51]. European Crohn’s and Colitis Organisation guide-
lines discuss the use of cyclosporine as salvage therapy to 
avoid colectomy in pregnant patients with steroid-refrac-
tory fulminant UC flare [90], also this exceptional strat-
egy should be reserved for expert centers. Compared with 
cyclosporine, tacrolimus has less risk of maternal hyper-
tension but higher risk of neonatal hyperglycemia. 
Small Molecules
Tofacitinib is an oral, small molecule Janus kinase in-
hibitor used for the treatment of rheumatoid arthritis, pso-
riatic arthritis, and UC. As a small molecule, tofacitinib is 
likely to cross the placental barrier and animal studies dem-
onstrated teratogenicity. There are no controlled clinical 
studies designed to determine the effects of tofacitinib in 
pregnant women and prospectively collected registry data 
remain limited. Of 1,157 patients enrolled in the UC inter-
ventional studies, 301 were women of childbearing age. 
Eleven cases of maternal exposure and 14 cases of paternal 
exposure to tofacitinib (doses of 5 or 10 mg twice daily) 
were identified. Outcomes included 15 healthy newborns 
with no fetal deaths, neonatal deaths, and congenital mal-
formations reported. Two spontaneous abortions and 2 
medical terminations were described. Outcomes across 
other tofacitinib studies and postmarketing cases were 
consistent, with a healthy newborn being the most com-
mon outcome and no fetal deaths [91]. However, given rel-
atively few cases of pregnancy reported on this drug, con-
clusions cannot be drawn, and further studies are needed. 
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Biologic Agents
Biologic agents are IgG or fragments that are to a var-
ious extent actively transported across the placenta by 
the neonatal Fc receptor, which becomes functional at 
week 13 of gestation [92]. Eighty percentage of transfer 
occurs during the third trimester and fetal IgG concen-
trations are increased logarithmically from gestational 
week 20 to delivery [93–95]. As a consequence of this 
active transport across the placenta, cord blood biologics 
concentrations can exceed maternal levels by up to 4-fold 
at birth and may be detectable in children for up to 
12 months [66], raising concern about possible adverse 
effects on the development of the immune system of the 
infant [96]. Organogenesis occurs before transplacental 
anti-TNF drug transfer and to date no association was 
observed between congenital malformations and biolog-
ic agents. 
Anti-TNF Agents
The 4 anti-TNFs approved in IBD are IFX, ADA, cer-
tolizumab pegol (CZP), and golimumab. CZP differs 
from the others in that it is a pegylated Fab fragment an-
ti-TNF agent. This results in clinically insignificant drug 
levels in infants. Series on > 100 IBD patients exposed 
during pregnancy to IFX [97], ADA [98], and CZP [99] 
found no adverse effect on pregnancy outcomes. Golim-
umab is supposed to have a similar safety profile. To date, 
no evidence was found for an association between treat-
ment with TNF-α inhibitors for IBD in pregnancy and 
risk of congenital anomalies compared with disease-
matched pregnancies. More than 500 women in the on-
going PIANO registry have been exposed to the afore-
mentioned anti-TNF medications during pregnancy, and 
no increased risk with adverse pregnancy outcomes was 
observed [88]. A systematic review by Nielsen et al. [94] 
was consistent with these finding with no miscarriages, 
preterm deliveries, stillbirth, low birth weight, congenital 
malformations, and/or infections noted even when the 
drug was administered during the third trimester. A re-
cent meta-analysis of 5 studies with 1,216 IBD patients 
neither found an increase in adverse outcomes in women 
taking anti-TNF therapy compared with unexposed con-
trols (OR 1.00; 95% CI 0.72–1.41), including preterm de-
livery (OR 1.00; 95% CI 0.62–1.62), low birth weight (OR 
1.05; 95% CI 0.62–1.78), and congenital anomalies (OR 
1.10; 95% CI 0.58–2.09) [100]. However, women receiv-
ing an anti-TNF in combination with thiopurine had 
higher risk of preterm delivery (OR 2.4; 95% CI 1.3–4.3) 
and pregnancy complication (OR 1.7; 95% CI 1.0–2.2) 
compared with unexposed women [100]. These observa-
tions reflect also probably that these patients had a more 
active disease. In addition, a risk of delayed infant infec-
tions was reported.
Anti-integrin Agents
Vedolizumab (VDZ) is a gut-selective humanized 
IgG-1 monoclonal antibody to α4β7 integrin approved 
for both CD and UC. A reproductive study of VDZ in 
pregnant primates demonstrated no evidence of adverse 
effects on development after intravenous administration 
of VDZ at doses 20 times the equivalent of those recom-
mended for humans [101]. To date, we have limited data 
available on human pregnancy safety. A recent case series 
described the evolution of 24 VDZ treated pregnancies. 
No new safety concerns for pregnancy outcomes in fe-
males directly or indirectly exposed to VDZ were ob-
served [102]. An international retrospective study report-
ed pregnancy and neonatal complication in 24 women 
treated with VDZ with 12 live births, 4 spontaneous abor-
tions, and 5 elective abortions [103]. More recently, the 
same group conduced a retrospective European study 
where gastroenterologists were asked to report all VDZ 
exposed pregnancies as well as neonatal outcomes 
through an electronic case report form. There was no dif-
ference in miscarriage rates between the VDZ exposed 
group and a control group of patients exposed to anti-
TNF (16 vs. 13%, p = 0.71) or a control group of patients 
neither exposed to immunosuppressors nor to biologics 
(16 vs. 10%, p = 0.236). After exclusion of patients with 
active disease, the number of miscarriages was similar be-
tween VDZ group and patients in other groups [104]. 
Therefore, active disease in pregnancy rather than drug 
effect seems to have been the driver of this adverse preg-
nancy outcome. Experts suggest to use VDZ for women 
of childbearing age if indicated. Still, if the childbearing 
age woman is bionaive, most data are available with anti-
TNF agents, and therefore maybe anti-TNF, and espe-
cially CZP are most appropriate as first-line treatment 
option. 
Anti-Interleukin IL-12–23
Ustekinumab is an IgG1 monoclonal anti-interleukin 
12–23 antibody approved for psoriasis, psoriatic arthritis, 
and more recently for CD. A series of 26 exposed preg-
nancies reported 5 spontaneous abortions (19%), a rate 
that is similar to the general population [105]. A cohort 
of 226 women treated with Ustekinumab for psoriasis or 
CD will be presented this year and no specific signal is 






To Stop or Not to Stop Treatment during Pregnancy: 
Is the Debate Over?
The strategy regarding the discontinuation of anti-
TNF therapy early during pregnancy poses several prob-
lems. Stopping treatment is associated with a higher risk 
of a flare during pregnancy and during the postpartum 
period and increase in the risk of developing antibodies 
due to lower trough levels leading possibly to loss of re-
sponse to the drug after resuming treatment. 
Discontinuation of anti-TNF-α during pregnancy may 
be considered under certain circumstances in patients 
who are at very low risk of relapse with an objective sus-
tained endoscopic remission since < 6 months before con-
ception, no previous loss of response to anti-TNFs or 
need for dose optimization, appropriate therapeutic lev-
els before conception, no hospitalization in the last 
3 years, and no prior bowel resection [107].
As mentioned previously, there is no evidence that 
continuing anti-TNF therapy during pregnancy has a 
negative impact on the pregnancy or children’s outcomes 
[108, 109]. In patients with active disease during the sec-
ond trimester, the benefit of continuing anti-TNF thera-
py during the third trimester outweighs the potential risk 
[26, 88, 89]. To minimize transplacental transfer near the 
time of delivery, biologic dosing can be adjusted to achieve 
trough or lowest serum drug concentrations at the esti-
mated date. Although this strategy is probably safe, we do 
not have solid data to confirm it, and this is why most 
experts agree to stop biological therapies around week 20 
in patients in remission (Table 1) [26].
Delivery Mode 
Women with IBD have twice as many cesarean deliv-
eries as women in the general population [31]. Most of the 
time, a caesarean section is proposed or requested be-
cause of unjustified fears on the part of patients or care 
providers. Also there is no contraindication to vaginal de-
livery in the majority of cases [110], a healthy IBD patient 
should be able to have a successful vaginal delivery. Epi-
siotomy should be avoided whenever possible as it can 
trigger perianal disease. Women with active perianal or 
rectal disease involvement and open rectovaginal fistula 
at the time of delivery should however have planned ce-
sarean section [111]. In this population caesarean deliv-
ery should be performed by a senior obstetrician in order 
to decrease the risk of intraoperative organ injury. IPAA 
is a relative contraindication for vaginal delivery.
Postpartum Period and Lactation
Postpartum
The risk of disease relapse is higher in the postpar-
tum period. This risk is mainly a consequence of dis-
continuation of IBD therapies during pregnancy with 
extended period of time before resuming treatment 
during the postpartum period [112]. In the pregnant 
IBD population from the French GETAID cohort, 14% 
of women who discontinued anti-TNF treatment be-
fore week 30 of gestation while in remission experi-
enced a relapse during the last trimester of pregnancy 
with a complicated disease course in 75% of cases 
(8 cases of prematurity and 1 case of colectomy for se-
vere acute colitis) and a third of them had a flare dur-
ing the early post-partum period before week 3. The 
relapse rate was 26% in the early postpartum period 
among women who continued anti-TNF therapy 
throughout pregnancy because of active disease [113]. 
In the absence of infectious complications, biological 
treatment could be resumed 24 h after vaginal delivery 
and 48 h after cesarean delivery [27]. For weight-based 
dosing treatments, it is usually recommended to con-
sider the mother’s weight before pregnancy. The dose 
will then be adjusted according to several factors in-
cluding disease activity, possible persistent weight gain 
postpartum and serum concentrations. Other IBD 
treatments can be continued in the postpartum period. 
MTX can be restarted postpartum if the mother is not 
lactating [114]. 
After a cesarean delivery, patients are at higher risk of 
developing an ileus, especially patients with IPAA in 
whom the pouch was manipulated during the delivery. 
Supportive measures and early feeding may decrease this 
risk [115]. Patients with an ostomy are more at risk of 
stoma complications during pregnancy and after deliv-
ery. It is recommended to avoid excessive weight gain 
during pregnancy and seek for advice to colorectal sur-
geon and a specialist nurse [114]. In case of cesarean sec-
tion, simply covering the ostomy with gauze is sufficient 
to protect the operative field [116].
Lactation
A significant number of women with IBD do not 
breastfeed their children despite the fact that benefits of 
breastfeeding have been demonstrated to be substantial 
to both mother and child [117].
The relationship between breastfeeding and disease 
activity usually reflects the consequence of IBD thera-
pies discontinuation, as 60% of women discontinued 
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their medications in the postpartum period for fear of 
medication transmission in breast milk [66, 111]. In the 
PIANO registry, the breastfeeding rate was significantly 
lower in women on immunomodulators and biologic 
treatments [118]. Although, literature is sparse in this 
field and long-term safety data are missing, the vast ma-
jority of medications prescribed for IBD are either un-
detectable in breast milk or present in concentrations 
that would not be expected to harm the breastfeeding 
infant (Table 2) [114]. Clinicians can rely on LactMed, 
which is a free online database sponsored by the US Na-
tional Library of Medicine, that provides reliable infor-
Table 2. IBD treatment and breastfeeding (adapted from [27] and [114])
Drug Breast milk drug concentration and safety Comments
Antibiotics
Amoxicillin with clavulanic acid Enters breast milk. Monitor child for diarrhea 
and rash
Compatible
Ciprofloxacin Enters breast milk. Monitor child for diarrhea 
and rash
Compatible but delay feeding 3–4 h after dose
Metronidazole Enters breast milk, possible mutagenicity Contraindicated
Rifaximinin Unlikely to reach breastmilk. No human data Avoid
Aminosalicylates Poorly excreted into milk. Rare reports of 
diarrhea
Compatible. Maintain same dosing
Corticosteroids (budesonide, prednisone, prednisolone) Dose-dependent levels in milk. Prednisolone 
preferred for high-dose therapy
Compatible but delay feeding 3–4 h after dose for 
doses >20 mg
Immunomodulators
Cyclosporine Variable, but breastfed infant receives <2% of 
mother’s weight-adjusted dose
Probably compatible but infant levels should be 
monitored
Methotrexate Low dose likely results in low milk 
concentration
Contraindicated based on concerns for high-dose 
exposure
Thiopurines (azathioprine, 6-mercaptopurine) Low levels in milk and undetectable after 4 h Compatible. Delay feeding for 4 h after dose 
recommended
Small molecules
Tofacitinib Unknown. No human data
Biologics
Anti-TNF-α
IFX Low levels in milk Compatible. Maintain same dosing
≤ 0.5% of mother’s plasma concentration
Peak excretion 1–4 day post infusion
ADA Low levels in milk Compatible. Maintain same dosing
<1% of mother’s plasma concentration
Peak excretion 1–6 day postinjection
GM Low or undetectable levels in milk Compatible. Maintain same dosing
CZP Very low or undetectable levels in milk Compatible. Maintain same dosing
Peak excretion 0.5–2 day postinjection
Anti-integrin
VDZ Low or undetectable levels in milk Probably compatible. Maintain same dosing
<1% of mother’s plasma concentration
Peak excretion 3–7 day postinjection
Anti-interleukins
UST Low or undetectable levels in milk
Peak excretion 1 postinjection
Probably compatible. Maintain same dosing





mation on drugs and lactation. Treatments derived 
from mesalamine are generally found in the milk but 
are well tolerated. Only isolated cases of diarrhea were 
reported in exposed children. 5-ASA agents (mesala-
mine, balsalazide, and olsalazine) can therefore be con-
tinued during lactation. Those formulations are pre-
ferred to sulfasalazine due to the unknown side effects 
of drug metabolite, which are excreted into milk at con-
centrations that are higher than in the mother and 
known for hemolytic and antimicrobial properties. Cor-
ticosteroids low dose and thiopurines are detected in 
small amounts in the milk [119]. Some data suggest that 
higher dose of prednisone (> 20 mg/day) can result in 
higher levels in the breastfed infant and cause tempo-
rary loss of milk supply. Thiopurines are not detected in 
breast milk 4 h from dosing. Although it is not abso-
lutely necessary, some experts recommend avoiding 
breastfeeding 3–4 h after taking these medications in 
order to limit the amount of drug transmitted onto the 
child. In most studies, the concentrations of biological 
agents found in milk are minimal (< 1% of serum con-
centration) as the drug is degraded in the stomach of 
the child and no harm from breastfeeding on biologic 
therapies has been described [120]. Data for anti-inter-
leukin 12–23 and anti-integrin are very limited but due 
to limited transfer detectable and their monoclonal an-
tibody molecular structures it is presumed that they are 
compatible with lactation [121, 122]. Women on tofaci-
tinib are advised not to breastfeed due to the lack of data 
on this molecule during the lactation period. The rec-
ommended duration of breastfeeding is the same as for 
women without IBD. Exclusive breastfeeding for 
6 months, with continuation of breastfeeding for 1 year 
or longer as mutually desired by mother and infant is 
recommended for all mothers by the American Acade-
my of Pediatrics. 
Approach to the Pregnant Woman with IBD 
It is now well established that preconception counsel-
ing associated to a multidisciplinary approach involving 
all providers, leading to better outcomes and less anxiety 
among IBD patients. When different healthcare provid-
ers and/or family provide contradictory advice, patients 
are most likely to experience anxiety. Preconception 
counseling has been associated with increased compli-
ance with medications, disease control, and improved 
outcomes [29].
Preconception Counseling
IBD patients in childbearing age should always be 
asked if they have a pregnancy plan in the near future. 
In this way, the gastroenterologist will be able to take 
the time to reassure the patient about the safety of most 
treatments used during pregnancy and lactation. He 
will also have the opportunity to reassess disease activ-
ity and achieve remission before attempting concep-
tion. Laboratory analysis, dosage of FC, and endoscopy 
prior to conception, if endoscopic remission has not 
been assessed before, should be part of the workup. 
This is also a good moment to ensure that basic care has 
been provided such as screening for anemia and vita-
min deficiency, vaccinations update, supplementation 
for folic acid, and smoking cessation. At this point, Asa-
col should be replaced by another Mesalamine formula-
tion (Fig. 1). 
Management during Pregnancy
The risk of adverse outcomes is increased in woman 
with IBD during the pregnancy, even if their disease is in 
endoscopic remission [123]. Therefore, close monitoring 
is recommended during pregnancy in this high-risk pop-
ulation. 
In each trimester, FC and serum inflammatory mark-
ers, as well as gestational weight gain, should be moni-
tored for evidence of disease activity and poor nutrition. 
If available, a trough level of biologic agent can be 
checked in the late second trimester to determine timing 
and dose of biologic agent in the third trimester. In the 
third trimester as well as in the postpartum, the pediatri-
cian should be informed that live vaccines are contrain-
dicated in infant exposed to biologic treatments. The 
management of flares would be similar to the nonpreg-
nant patient with the exception that traditional serum 
markers of disease activity, such as sedimentation rate, 
hemoglobin, and albumin, are abnormal in pregnancy 
(Fig. 2). 
Impact of IBD for the Baby
IBD and Heredity
Genetic risk of CD is higher than for UC in European 
cohort studies. Having multiple family members with 
IBD increases the risk for children with IBD. In monozy-
gotic twins studies, 20–56% of CD and 6–19% of UC had 
concordance [124]. With maternal CD, incidence rate 
ratio for CD is 6.3 in offspring, and the absolute risk of 
an offspring developing CD is 2.7%. With maternal UC, 




     Clinical assessment
     Objective assessment with at least biomarkers (CRP, FC)
     Consider endoscopy and imaging
Preconception counseling
Active disease:
     Discuss risks of infertility,
    worsening disease activity
    and consequences on
    pregnancy outcomes
     Delay conception and
    recommend
    contraception
Inactive disease




     Confirm adherence
     Modify treatment to















     Discuss fertility
     Discontinue teratogenic
    medications
     Iron and folic acid
    supplementation and ensure
    adequate caloric and vitamins
    levels
     Optimize management of
    comorbidities
     Update immunization status
     Cessation of tobacco, alcohol and
    illicit drugs
     Discuss risk/benefit ratio of IBD
    medication during pregnancy
    and lactation
     Discuss mode of delivery
     Discuss treatment plan with
    family doctor and obstetrician
Fig. 1. Algorithm of care during preconception period (adapted from [114]). CRP, C-reactive protein; FC, fecal 
calprotectin; MTX, methotrexate; 5-ASA, 5-amino-salacylic acid; DPB, dibutyl phthalate; IBD, inflammatory 
bowel disease.
9 months follow-up
IBD in clinical remission
Trimester 1 
 Check iron/B12 levels, adequate
folic acid supplementation
 Nutrition consult if needed (short
bowel, ostomy…)
 GI visit
 Labs: CBC, liver enzymes, albumin,
CRP
 5-ASA, thiopurines and biologics to




    Vaginal: biologics can be resumed 24 h post delivery if no infection
    Cesarean: biologics can be resumed 48 h post-delivery if no infection.
    Measures to prevent ileus and wound infection.
    Anticoagulant prophylaxis for VTE
Trimester 2
 GI visit
 Labs: CBC, liver enzymes,
albumin, CRP
 TDM and can time last





 Last dose of
biologics based on
TDM (cf table 1)
 GI follow-up every 2 weeks
 Monitor labs, calprotectin
 Nutrition counseling
 Management of the flare:
      GA <37 weeks: same medical
     therapy as usual to treat flare (steroids
     short period then Anti-TNF if naive
     or drug optimization)
     • GA ≥37 weeks: corticosteroid and
     consider deliver if non responder
     to steroids
Fig. 2. Algorithm of care during pregnancy (adapted from [114]). IBD, inflammatory bowel disease; CRP, C-
reactive protein; GI, gastroenterologist; CBC, complete blood count; TDM, therapeutic drug monitoring; GA, 





this incidence rate ratio is 3.7 for UC in an offspring, and 
the absolute risk of an offspring developing UC is 1.6% 
[125]. When both parents have the disease the risk of de-
veloping IBD rises to 30% [114]. Currently, no genetic 
test is available to predict whether the child will develop 
IBD.
Infection and Vaccination
Parents and pediatricians should be vigilant about 
infections, especially if the child was exposed to combi-
nation of thiopurines and biologics. A systematic re-
view of anti-TNF use during IBD pregnancies found no 
increased risk of infections in the first year of infant life 
[94]. However, individual cases of serious infection 
have been reported [47]. In the PIANO registry, there 
is 1 case of vertical histoplasmosis transfer involving a 
mother taking IFX 10 mg/kg every 6 weeks who had 
supratherapeutic IFX levels at birth. It is recommended 
to minimize unnecessary antibiotic exposure, as that 
may increase the risk of developing CD later in child-
hood. Clinically significant levels can be found in new-
born infants for up to 6 months after birth. Avoidance 
of live vaccines in infants exposed to biologic therapy 
during the third trimester of pregnancy is recommend-
ed until at least after 6 months because significant levels 
can be found in infants up to 6 months after birth and 
may lead to clinically relevant neonatal immunosup-
pression. The rotavirus vaccine postdelivery is the only 
live vaccine administered before 6 months in certain 
country such as in the United States. The first dose 
should be administered before 15 weeks of age to be 
more effective. 
Mental Development
No evidence suggests that babies born to mothers with 
IBD regardless of medication exposure have any develop-
mental delays. Data on developmental milestones from 
the PIANO registry support the lack of negative impact 
of IBD treatments on development. Moreover, infants 
with higher anti-TNF drug levels at birth had statistically 
superior achievement of developmental milestones com-
pared with infants with lower birth drug levels. The 
 hypothesis of effects of inflammation in utero on the de-
veloping brain has been reported and pro-inflammatory 
mediators negatively influence both hippocampal neuro-
genesis and neuronal cytoarchitecture during brain de-
velopment. The importance of good inflammatory con-
trol during pregnancy should therefore be emphasized 
when counseling women with IBD [126]. 
Conclusions
IBD affects patients during their peak reproduc-
tive years raising important questions, in both patients 
and healthcare providers, regarding conception, preg-
nancy, and breastfeeding. Lack of information and 
poor communication among healthcare providers can 
leave patients with limited information and contradic-
tory advice. Although there are clear limitations to 
the evidence base in this area, expert groups have none-
theless provided clear guidance on how best to an-
swer these questions. Gastroenterologists are a key re-
source to provide reassurance and guidance during 
this  important period of patients’ lives, and they 
should  work with other healthcare providers. The 
 overarching concept is that optimizing the mother’s 
health is critical for optimizing the health of the child 
and benefit of continuing medical therapy in IBD 
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